The Global Companion Diagnostic Market is estimated to grow with a strikingly impressive rate of 15.4% during the assessment period of 2017 to 2023. In its latest published report, Market Research Future (MRFR) minutely analyses and identifies the various factors driving the market growth. The factors identified as the contributory drivers of the market are the growing need for monitoring the safety and efficiency of drugs, increasing costs related to drug discovery and development, ameliorating demand for specific treatment methodologies of rare and chronic disorders, and advancing technologies in companion diagnostic devices. Moreover, the proliferating demand for diagnostic devices which boast the capability of detecting tumors in the initial stage of cancer is also driving the market’s growth.
Request Free Sample Copy at https://www.marketresearchfuture.com/sample_request/3077
On the flip side, lack of skilled professionals and technicians with such devices and lack of awareness in developing economies can pull down the growth percentage of the globular companion diagnostic market.
Companion Diagnostic refers to as therapeutic devices that are used to diagnosis the response of treatment in the patients as well as in vitro gadgets. These devices provide essential information that is required for the effective and safe use of corresponding medicine or biological product. The outcome as in the diagnostic report helps a health care professional to determine if the benefits of a particular therapeutic product will compensate with some potentially serious side effects or risks.
Fervent players leading the global companion diagnostics market include Agilent Technologies (U.S.), Abbott (U.S.), ARUP Laboratories (U.S.), Myriad Genetics Inc. (U.S.), F. Hoffmann-La Roche AG. (Germany), Thermo Fisher Scientific Inc. (U.S.), and Qiagen N.V. (Germany).
November 27, 2018 – Invivoscribe (US), an industry pioneer in developing and manufacturing diagnostic products announced the submission of the LeukoStrat® CDx FLT3 Mutation Assay to both the US FDA and the Japan PMDA (Pharmaceuticals and Medical Devices Agency) as the companion diagnostic for quizartinib.
LeukoStrat is developed in partnership with Daiichi Sankyo as the companion diagnostic that bridges to the global phase 3 QuANTUM-R clinical trial (United States, Europe, and Asia excluding Japan).
October 09, 2018 — Myriad Genetics, Inc. (US), a global leader in personalized medicine, announced signing of a commercialization plan with Pfizer Inc. (US), a pharmaceutical corporation that is under an existing companion diagnostic agreement, in which Myriad is pursuing U.S. Food and Drug Administration (FDA) approval for its BRACAnalysis CDx® to be used as a companion diagnostic with Pfizer’s investigational PARP (poly ADP ribose polymerase) inhibitor, talazoparib.
The segmentation of the global companion diagnostic market is segmented on the basis of technology, end-user, and application.
Get Full Report with Niche Segments and Top Players at https://www.marketresearchfuture.com/reports/companion-diagnostic-market-3077
By technology, the market comprises of In-situ hybridization, Polymerase chain reaction (PCR), and immunohistochemistry.
By end-user, the market includes clinical laboratories, pharmaceutical & biotech companies, CRO, and others.
By application, the market includes CNS diseases, cardiovascular diseases, cancer, infectious diseases, and others.
Geographical segmentation of the companion diagnostic market includes the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
Americas is the market leader of companion diagnostics in the global geographical segmentation. North America stands as the superior contributor in this region over Latin America owing to a number of impactful reasons. The expensive usage of advanced diagnostic services and an imperative need to come up with a solution for cancer diagnosis and treatment is driving the market growth of companion diagnostic devices.
With the second-largest regional market after Americas, Europe contributes majorly to the global companion diagnostic market growth. Factors such as the rising demand for efficiency in the healthcare sector and a strengthening healthcare system are massively contributing to the region’s growth. Germany holds the largest market position in Europe primarily because of the residing market players in the nation.
Continuous developments and increasing healthcare expenditure in developing economies like China and India have placed the Asia-Pacific region as the market with the fastest-growing potential. Wide-spread prevalence of lifestyle-based diseases like obesity, diabetes, and cancer to drive the market growth of this region. The Middle East & Africa region is anticipated to grow in a slow and steady manner due to low healthcare expenditure and demand related to primary healthcare services.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar